ArticleMethods in molecular biology (Clifton, N.J.)2026
Detection of Oxidized Macrophage Migration Inhibitory Factor (oxMIF) in Tissue Samples Using Immunohistochemistry (IHC).
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunohistochemistry (IHC) staining is a technique that exploits the specificity of antibodies to detect antigens (proteins) in tissue samples. This usually involves a tissue fixation step to prevent elution, degradation, or modification of the protein of interest. However, the fixation step denatures the protein, altering the characteristic structure. This is particularly problematic when detecting oxidized macrophage migration inhibitory factor (oxMIF), the pathogenic isoform of macrophage migration inhibitory factor (MIF). In the reduced state of MIF, the oxMIF antibody epitopes are hidden within the central pore of the trimeric structure and are thus inaccessible to antibodies. OxMIF is formed through an oxidative post-translational modification of MIF in the pro-oxidative environment of inflammatory processes, as well as in tumors. This oxidation leads to a change in the native conformation of MIF, exposing these epitopes and allowing the detection of oxMIF with anti-oxMIF antibodies. Therefore, sample preparation must not artificially induce structural changes to MIF to enable specific staining of oxMIF. Here, we describe a method for detecting oxMIF in cancer tissue using IHC with oxMIF-specific antibodies that exclude cross-reactivity with reduced MIF.
Indexed as
Identifiers
42129119What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.